MROH5 and Decreased total neutrophil count: We found that MROH5 was significantly associated with neutropenia in MAGMA gene analyses in patients treated with XELOX (P = 6.6 × 10−7) and was independently validated in those receiving XELOX + cetuximab; pooled P = 3.7 × 10−7.